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ABSTRACT
Objectives: This study aims to find the relationship between artemisinins and neuraminidase (NA) with molecular docking study and also to 
determine the most potent NA inhibitor from artemisinin and derivatives.
Methods: All ligands were sketched and optimized using Gaussian 03W with Hartree-Fock method basis sets 6-311G. Molecular docking was 
performed using AutoDock 4.2.3 toward NA in complexes with oseltamivir as co-crystal ligand. The main parameters used were the free energy of 
binding (∆G) and dissociation constant (Ki) as affinity marker.
Results: Artesunate provided most negative free ∆G and lowest Ki toward NA with −9.55 kcal/mol and 100.66 nM, respectively. Artesunate shows 
higher affinity than oseltamivir with interactions between artesunate and amino acids at position 246 had important influences on artesunate affinity 
toward NA from H5N1.
Conclusion: In silico molecular docking results indicated that artesunate could be considered as NA inhibitor and should be potential to be developed 
as anti-influenza particularly to H5N1 with oseltamivir resistance.
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INTRODUCTION
Although avian influenza is no longer a frightening disease due to the 
development of H5N1 antivirus including oseltamivir and zanamivir, 
mutations of H5N1 could increase the resistance of influenza antiviral 
currently available [1]. Several H5N1 mutations even not only cause 
resistance to common neuraminidase inhibitor (NAI) but also cause 
transmission of avian influenza become airborne [2]. Sooner or later, 
avian influenza resistance toward known influenza antivirus will 
spread, and the need for new antiviral could be inevitable [3].
Compared with hemagglutinin, NA is a more ideal target for the 
development of anti-influenza compounds. Like oseltamivir and 
zanamivir, early developed NAIs considered to be effective for treatment 
and prophylaxis of avian influenza with minor side effects [4,5]. Several 
mutations in NA could reduce NAIs sensitivity [6]. However, several 
mutations only affect specific NAIs. For example, H274Y mutation 
caused resistance to oseltamivir (754-fold increase) and peramivir 
(260-fold increase), indicated that NA was still had potency as anti-
influenza targets therapy [7].
Discovery of NAIs with oseltamivir-based compounds resulting in the 
development of several known NAIs with more effectiveness example 
like laninamivir, a long action NAI [8]. However, since almost every 
known NAIs share similar molecular structure, the potency of cross-
resistances between NAIs is still high [9,10]. Discovery of secondary 
metabolites from medicinal plants with antiviral especially anti-
influenza activity is a key to obtain new NAI with high effectiveness. 
Some herbs extract shows anti-influenza activity and appear to be 
safe for human consumption [11]. One of the traditional medicinal 
plants with potent antiviral activity was Artemisia annua or qinghaosu. 
Artemisinins, its main secondary metabolites was known for having 
several antiviral activities [12,13]. However, to date still, no researches 
linking between artemisinin and derivatives with anti-influenza 
properties toward NA inhibition. In this study, we conducted in silico 
study to determine the most potent artemisinin derivatives as NAI 
with molecular docking method. We have selected seven artemisinin 
derivatives as test ligands that already used as antimalarial therapy or 
still in preclinical phase. Our purpose is to obtain information about 
other therapeutics activity that could be developed as drug repurposing 
from these compound class.
METHODS
Preparation of ligands and receptor
Structures of artemether, artemisinin, artemisone, artemotil, artelinic 
acid, artesunate, and dihydroartemisinin were sketched using 
GaussView 3.08 Software from Gaussian, Inc. All structures were 
geometry optimized by Hartree-Fock method basis sets 6-311G with 
Gaussian 03 W Software from Gaussian, Inc. Geometry optimization 
provided the most ideal conformation of following compounds 
that approaching conformation of these compounds in nature [14]. 
Optimized structures format changed from .log to .pdb using Open 
Babel 2.3.2 Software [15]. Docking program used in this study was 
AutoDock 4.2.3 from the Scripps Research Institute [16]. The molecular 
structure of NA H5N1 in complexes with oseltamivir (protein data bank 
[PDB] ID 2HU4) was obtained from website of PDB www.rscb.org with 
oseltamivir binding site chosen as active site since this site already 
known for the development of NAI [17].
Validation of docking process
The method used for molecular docking validation was pose selection 
using co-crystal structure by redocking it into active site of NA protein. 
Thus, redocking was performed with oseltamivir on NA active site. 
The parameters observed in validation is root-mean-square deviation 
(RMSD) of each ligand co-crystal at selected binding site [18]. Docking 
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programs are preferred to predict results from experimental poses 
with RMSD no more than 2 Å. Smaller RMSD indicate that position of 
redocking ligand was closer to crystallography ligand [19,20].
Docking studies
Molecular docking for all test ligand performed in same way as 
validation process using with similar grid box size and position [21]. 
The main parameter used in docking process were free energy of 
binding (∆G), dissociation constant (Ki), amino acids residues, and 
number of hydrogen bonds. Ligand affinity to receptor in docking 
method was determined by ∆G and Ki scores. More negative ∆G and 
lower Ki indicated higher ligand affinity toward active site of used 
receptor [22-24]. Test ligand with the highest affinity was compared 
with validation result of co-crystal ligand of active site to determine the 
potency of test ligand as NAI [14].
RESULTS AND DISCUSSION
Docking validation was done with redocking method using AutoDock 
4.2.3. Validation was performed on the entire binding site using 
co-crystal ligand of selected receptor. Using of entire binding site was 
purposed to identify any other potential active site at NA receptor. 
However, redocking result showed that oseltamivir as cocrystal ligand 
docked into similar position like crystallography result [14].
Redocking results from this study were provided RMSD value wand 
almost at stacked position with crystallography results (Fig. 1), 
indicated that receptor 2HU4 was valid for molecular docking 
purpose [20]. Other parameters observed in validation was ∆G, Ki, 
amino acids residues, and number of hydrogen bonds of cocrystal 
ligand as shown in Table 1.
Test ligands were sketched and performed geometry optimization. 
Hartree-Fock method was used with basis set 6-311G for geometry 
optimization (Table 2). This method was ab initio approximation with 
relatively high confidence rate for in silico analysis [14].
Docking was performed using AutoDock 4.2.3 at active site of NA 
receptor with 100 genetic algorithms runs to improve accuracy of 
docking result [16]. For each test ligand, one poses with most negative 
∆G and lowest Ki was selected as representatives of test ligand [14]. The 
docking results data of seven ligands to NA were compared each other 
as shown in Table 3. Compared to other ligands, artesunate had the 
most negative ∆G and lowest Ki, thus had the highest affinity toward NA 
than other artemisinin derivatives. All ligands also provided negative 
score of ∆G, indicated that interaction between NA receptor active site 
and ligands will occur spontaneously [19].
Comparison of amino acids residues and number of hydrogen bonds 
between docking results of oseltamivir as co-crystal ligand and 
artesunate as test ligand then performed to analyzed similarities and 
differences between docking results of two compounds. Comparison 
results shown in Table 4 indicated slight differences in amino acids 
residues and number of hydrogen bonds between oseltamivir and 
artesunate docking results. Interestingly, artesunate had slight higher 
affinity than oseltamivir.
Whether artesunate had the same activity with oseltamivir or not was 
still unclear. However, since most amino acids residues which interacted 
with oseltamivir also interacted with artesunate (8 out of 10), there was 
possible that artesunate also inhibits NA like oseltamivir [25]. Since NA 
inhibition was one of primary target for influenza therapy, this study 
results indicated that artesunate had potency as NAI.
There is only one amino acid residue that forms in docking result of 
artesunate in position 246, which do not occurs in other ligands docking 
result. As comparison, docking result of artemisone had many similarity 
with docking result of artesunate, the differences occurs only in 3 out 
of 13 amino acids residues despite artesunate gave much number of 
hydrogen bonds than artemisone. However, compared to artesunate, 
artemisone gave lower affinity toward NA receptor active site (Table 3). 
This result proved that presence interaction at amino acid residue in 
position 246 had important influence on artesunate affinity toward NA 
receptor.
More observation conducted to reveal interaction between artesunate 
and NA receptor active site as shown in Fig. 2. Artesunate was docked 
into cleavage between set of β-strand peptides (yellow in left Fig. 2) 
in N-terminal lobes of tyrosine kinase domain. On the other hand, 
interactions between artesunate and amino acids residues dominated 
with hydrophilic interactions with five hydrogen bonds formed (right 
Fig. 2), even more than oseltamivir (Table 4). We also compared 
position of artesunate with oseltamivir directly which obtained from 
Fig. 1: Results of validation from oseltamivir and neuraminidase; 
root-mean-square deviation=1.183 Å (Red: Oseltamivir redocking 
result; Blue: Oseltamivir crystallography result)
Fig. 2: Docking results of artesunate and neuraminidase (NA) 
(Left: Artesunate position in NA; Right: Interactions between 
artesunate and amino acids residues of NA receptor active site)
Table 1: Validation results of NA receptors PDB ID 2HU4 with co-crystal ligand oseltamivir
Receptor Ligand RMSD (Å) ∆G (kcal/mol) Ki (µM) Amino acids residues Number of 
hydrogen bonds
NA Oseltamivir 1.183 −9.26 0.16253 118-Arg, 119-Glu, 151-Asp, 152-Arg, 178-Trp, 224-Arg, 
277-Glu, 292-Arg, 371-Arg, 406-Tyr
4
NA: Neuraminidase, PDB: Protein data bank, RMSD: Root-mean-square deviation, ∆G: Energy of binding, Ki: Dissociation constant
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Table 2: 2D and 3D structure of ligands
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redocking method. As result, we overlay both docking results structure 
as shown in Fig. 3.
Both artesunate and oseltamivir docked into similar position at the 
active site of NA receptor active site. However, endoperoxide chain 
of artesunate had different behavior with side chain of oseltamivir. 
Aside from other artemisinins, interactions of artesunate and NA 
were dominated by interactions at amino acid’s in position 224-277 
(Table 4). Total six interactions were formed in artesunate compared 
with two in oseltamivir. This results could lead in conclusion that 
artesunate had higher affinity toward NA than oseltamivir caused 
by more interactions occurred at those position. Hence, interactions 
at amino acids residues number 224-277 could have important 
influences toward activity as NAI, primarily amino acid serine at 
position 246.
CONCLUSION
This study was successfully described linking between artemisinin and 
derivatives with NA, even gave interesting result where artesunate had 
higher affinity than oseltamivir at NA active site. Artesunate provided 
ΔG and Ki -9.55 kcal/mol and 100.66 nM, respectively. These result 
open up opportunities to develop artesunate as potent anti-influenza 
especially one with oseltamivir resistance. More researches should 
be done to optimize the interactions mainly in amino acid position 
224-277, especially with 246-serine. Designing novel NAI derives 
from artesunate should be focus at those amino acids residues. Thus, 
this study clearly indicates a promising potential of artemisinin and 
derivatives to be develop as NAI for anti-influenza therapy.
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